Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I–II cervical cancer: a meta-analysis

Shu-Li Yang1, Ling Chen2, Yue He1, Hui Zhao1 and Yu-Mei Wu1

Abstract

Objective: In this meta-analysis, we aimed to evaluate the oncological outcomes of preoperative neoadjuvant chemotherapy followed by radical surgery compared with radical surgery alone for treatment of International Federation of Gynecology and Obstetrics (FIGO) stage I–II cervical cancer.

Method: We searched for studies comparing the safety and efficacy of neoadjuvant chemotherapy plus surgery versus surgery alone in treatment outcomes of locally advanced cervical cancer. Meta-analysis was used to calculate the pooled odds ratios with corresponding 95% confidence intervals (CI).

Results: Sixteen studies were included in our analysis. Pooled analysis of overall survival rate [odds ratio (OR) = 1.09, 95% CI: 0.83–1.43] and progression-free survival rate (OR = 1.10, 95% CI: 0.77–1.57) showed that preoperative neoadjuvant chemotherapy did not have a benefit compared with surgery alone in terms of survival rates. The pooled results for postoperative parameters indicated that preoperative neoadjuvant chemotherapy followed by radical surgery was associated with a high rate of vascular space involvement (OR = 0.25, 95% CI: 0.17–0.35) and parametrial infiltration (OR = 0.60, 95% CI: 0.45–0.79).

Conclusions: This meta-analysis indicated that surgery following neoadjuvant chemotherapy for FIGO stage I–II cervical cancer and surgery alone had similar oncological outcomes.

1Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
2Guangzhou Red Cross Hospital, Guangzhou, China

Corresponding author:
Yu-Mei Wu, Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No. 17 Qihelou Street, Dongcheng District, Beijing 100006, China.
Email: wym597118@163.com
Introduction
Cervical cancer is a frequent cancer-related cause of death in women in developing countries.\textsuperscript{1} For patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ia–Ib1 cervical cancer, radical surgery is recognized as the standard therapy, and the 5 year survival rate of patients may be as high as 80% to 90%.\textsuperscript{2,3} Pelvic relapse is the most common negative outcome after radical surgery for cervical carcinoma. Patients with disease at FIGO stage Ib2 and above undergo radiation therapy rather than radical surgery because of the potential for postoperative complications such as parametrial involvement, lymph node metastases, and positive surgical margins. Although radiotherapy can have the same effect as surgery, injury to surrounding tissues caused by radiation may harm ovarian function and sexual capacity, which significantly affects patients’ quality of life.

With the goal of improving efficacy for patients with cervical cancer, previous trials have been conducted to compare neoadjuvant therapy with surgery alone.\textsuperscript{4–6} Neoadjuvant chemotherapy (NACT) followed by radical surgery therapy (RST) has become a popular option for treatment of cervical cancer.\textsuperscript{7}

NACT, also called early or prechemotherapy, is used to reduce tumor volume before surgery or radiotherapy. For advanced-stage cervical cancer, two to three cycles of NACT can help increase the success rate of surgical resection. Previous trials have indicated that NACT can eliminate tumor micro-metastases, shrink tumor volume, improve the resection rate, and achieve surgical down-staging of patients.\textsuperscript{8} A previous meta-analysis\textsuperscript{9} revealed that neoadjuvant chemotherapy with radical surgery increased survival rates and decreased local and distant recurrence rates in patients with stage Ib2–IIb cervical cancer. However, some studies have failed to show benefits of neoadjuvant therapy, and, in some cases, have shown unfavorable effects on efficacy.\textsuperscript{10,11} To date, there is no agreement on whether NACT significantly improves the prognosis of patients with cervical cancer.

The aim of our study was to compare the efficacy of NACT followed by RST with RST alone in patients with stage I to II cervical cancer.

Materials and methods
Ethical approval
The study did not require ethical board approval because it did not include human or animal trials.

Search strategy
We conducted a systematic screening using the electronic databases PubMed, Embase, and Cochrane Library up to September 2019. The process was based on MeSH terms and keywords “cervical cancer,” “neoadjuvant chemotherapy,” and “surgery”. We also searched the references.
of eligible publications that dealt with the topic of interest to identify additional relevant studies. We performed the current meta-analysis based on the Cochrane Handbook for Systematic Reviews of Interventions\textsuperscript{12} and Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.\textsuperscript{13} Meanwhile, we did not register our study with PROSPERO before screening studies for inclusion.

Eligibility criteria

Inclusion criteria were articles relating to (1) studies focused on comparing NACT + RST and RST; (2) reports of patients clinically diagnosed with early or locally advanced (stage I–II) cervical cancer; (3) studies that included data on surgery-related outcomes and postoperative specimens for both groups; (4) and studies with full texts available.

Quality assessment

Study quality was assessed separately by two investigators using the “Risk of bias” assessment tool from the Cochrane Collaboration for further justification.\textsuperscript{14}

Data extraction

Two authors independently extracted the relevant data from each trial based on the inclusion criteria. Differences were settled by consensus. We extracted the following information: name of the first author; year of publication; number of recruited participants; country; study period; histological type of the patients; tumor stage; results of interest including intraoperative parameters, complications, and pain scores.

Statistical analysis

The meta-analysis was conducted using Review Manager version 5.3 software (Revman; Cochrane Collaboration, Oxford, UK). A sensitivity analysis was conducted depending on the degree of heterogeneity across the included trials. Heterogeneity of the trial results was assessed using the $I^2$ statistic to select the ideal analysis model.\textsuperscript{14} Studies with an $I^2 \geq 50\%$ suggested high heterogeneity, and those with $I^2 < 50\%$ indicated low heterogeneity.\textsuperscript{15} When there was low heterogeneity among trials, the fixed-effects model was used. Otherwise, the random effects model was used. A $P$-value $< 0.05$ was used to identify a statistically significant difference.

Results

Overview of literature search and study characteristics

In total, 392 publications were initially identified. According to the criteria described in the methods, 22 articles were evaluated in more detail but some failed to provide detailed results. Finally, 16 studies\textsuperscript{16–31} were included in this meta-analysis. Table 1 provides a brief description of these studies. Figure 1 shows the search process, and Figure 2 and Figure 3 summarize the quality assessment processes.

Clinical and methodological heterogeneity

Survival and recurrence rates. Data on rates of survival are shown in Figure 4a and 4b. The results showed that preoperative neoadjuvant chemotherapy plus surgery (NACT+RST) was not better than RST alone; the groups did not differ in overall survival rate [odds ratio (OR) = 1.09, 95\% confidence interval (CI): 0.83–1.43] or progression-free survival rate (OR = 1.10, 95\% CI: 0.77–1.57).

The fixed-effects model was used to pool recurrence rate data because there was low heterogeneity across the studies. The pooled data showed that there was no significant difference between NACT+RST and RST
Table 1. Primary characteristics of the eligible studies.

| Author                  | Country | Research period (year/month) | Tumor stage | Number of patients | Mean age (years) | Treatment regimen | Type of study |
|-------------------------|---------|------------------------------|-------------|--------------------|------------------|-------------------|---------------|
| Serur et al., 1997      | USA     | 1987/1–1993/12               | Ib2         | 20                 | 47.8             | SCC               | BP, LP        |
| Behtash et al., 2006    | Iran    | 1996/3–2004/3                | Ib-IIa      | 22                 | 48               | SCC+ACC           | VP, RS        |
| Cai et al., 2006        | China   | 1999/1–2001/12               | Ib          | 52                 | 45.6             | SCC+ACC           | 5 FU–cisplatin, RCT |
| Eddy et al., 2007       | USA     | 1996/12–1999/1               | Ib          | 145                | —                | SCC+ACC+ASC      | NACT, RCT     |
| Sardi et al., 1997      | Argentina | 1987/5–1992/12              | Ib          | 102                | 39               | SCC               | BOMP, RCT     |
| Chen et al., 2008       | China   | 1999–2004                    | Ib2-IIb     | 72                 | 44               | SCC+ACC+ASC      | MP, RCT       |
| Cho et al., 2009        | Korea   | 1999/11–2007/9               | Ib2-IIa     | 51                 | 47.8             | SCC+ACC+ASC      | IP, TP, RS    |
| Lee et al., 2011        | Korea   | 2000/1–2006/12               | Ib-IIa      | 33                 | 47.5             | SCC+ACC+ASC      | TR 5 FU–cisplatin, RS |
| Wang et al., 2011       | China   | 2006/1–2010/2                | Ib2-IIb     | 68                 | 45.7             | SCC+ACC+ASC      | BR, TP, RS    |
| Kim et al., 2011        | Korea   | 2000–2008                    | Ib1-IIa     | 451                | 50.6             | SCC+ACC+ASC      | TR 5 FU–cisplatin, RS |
| Wen et al., 2012        | China   | 2006/1–2009/12               | Ib2-IIa     | 31                 | 45.68            | SCC+ACC           | 5 FU–cisplatin, RCT |
| Prueksaritanond et al., 2012 | Thailand | 2000/1–2009/12              | Ib2-IIa     | 40                 | 42.98            | SCC+ACC           | TP, PS        |
| Katsumata et al., 2013  | Japan   | 2001/12–2005/7               | Ib2-IIb     | 67                 | 47               | SCC+ASC           | BOMP, RCT     |
| Bogani et al., 2014     | Italy   | 2007/2–2014/3                | Ib2-IIb     | 20                 | 46.5             | SCC+ACC+ASC      | IP, TP, PS    |
| Yang et al., 2016       | China   | 2010/9–2012/7                | Ib-IIb      | 109                | 47               | SCC+ACC+ASC      | IP, TP, RCT   |
| Zhao et al., 2019       | China   | 2009/1–2016/12               | Ib2/IIa2    | 178                | 45.1             | SCC+ACC+ASC      | IP, BR, BOMP, RS |

NACT, neoadjuvant chemotherapy treatment; RST, radical surgery treatment; SCC, squamous carcinoma cell; ACC, adenocarcinoma; ASC, adenosquamous carcinoma; 5 FU, 5-fluorouracil; IP, irinotecan combined with cisplatin; TP, paclitaxel combined with cisplatin; VP, vincristine combined with cisplatin; MP, mitomycin combined with cisplatin; BP, bleomycin combined with cisplatin; LP, leucovorin combined with cisplatin; BOMP, bleomycin + vincristine + mitomycin combined with cisplatin; NACT, vincristine-cisplatin chemotherapy; PS, prospective study; RS, retrospective study; RCT, randomized controlled trial.
groups (OR = 0.98, 95% CI: 0.74–1.32) (Figure 4c).

Duration of surgery and blood loss. The pooled data showed no difference in duration of surgery [mean difference (MD) = 0.10, 95% CI: −0.04 to 0.24] between the NACT+RST and RST groups (Figure 4d). The blood loss rate was available for eight trials. No significant differences were observed between the NACT+RST group and the RST group in terms of blood loss.
rate (MD = 25.21, 95% CI: −76.47 to 126.90) (Figure 4e).

Vascular space involvement, parametrial infiltration, and lymph node metastasis. For the incidence of vascular space involvement, we found that NACT+RST was better than RST alone (OR = 0.25, 95% CI: 0.17–0.35; P < 0.00001) (Figure 4f). The pooled results indicated that there was a significant difference in the rate of parametrial infiltration between the two groups, and NACT+RST was better than RST alone (OR = 0.60, 95% CI: 0.45–0.79; P = 0.0004) (Figure 4g). In the analysis of the rate of lymph node metastasis, no significant difference was found between the NACT+RST and RST groups (OR = 0.65, 95% CI: 0.39–1.06) (Figure 4h).

Discussion

Cervical cancer is the most commonly diagnosed tumor in developing countries and is the fourth leading cause of cancer-related death among women.1,32 For early-stage cervical carcinoma (stages Ia, Ib1, IIa1), surgery is accepted as the most effective therapeutic treatment. However, the use of surgery is limited to patients with locally advanced cervical cancer (LACC, stages Ib2, IIa2, IIb).33

Since the late 1980s, NACT before surgery has been an effective option for LACC, being effective in shrinking tumor volume, preventing micro-metastases, improving surgical feasibility, and decreasing the disease stage of patients.8,34,35 Nevertheless, recent studies that compared NACT+RST with RST alone have shown different results,18,22,25 and the efficacy of NACT remains unclear. Thus, the present meta-analysis aimed to evaluate the effectiveness and safety of NACT and RST by pooling data from published studies and providing a reference for cervical cancer patients.

Many previous studies have shown that NACT reduces the risk of pathologic factors, thereby reducing the rate of postoperative radiation and chemotherapy30,36–38 and improving patients’ quality of life. Our data were consistent with these
Figure 3. Methodological quality assessment for included studies.

Figure 4. Pooled analysis of (a) overall survival rate; (b) progression-free survival rate; (c) recurrence rate; (d) duration of surgery; (e) blood loss; (f) vascular space involvement; (g) parametrial infiltration; and (h) lymph node metastasis for NACT+RST versus RST. The box indicates the weight of the study, the lines indicate 95% CI, and the diamond indicates the total effect. NACT, neoadjuvant chemotherapy treatment; RST, radical surgery treatment.
pathologic risk factors, and no significant differences in lymph node metastasis, duration of surgery, intraoperative blood loss, or recurrence rate were found between the NACT+RST group and the RST group, showing that NACT could reduce the surgical risk of LACC, without increasing the difficulty of surgery. In clinical practice, a surgeon often finds local adhesions surrounding the uterine artery and ureter, which can increase the difficulty of the surgery. Nevertheless, this phenomenon is not observed in all patients. One possible explanation is that the combination treatment was mainly used in patients with more severe local lesions, in whom artery embolization blocked tumor blood supply and thus controlled local bleeding, enabling clear exposure, and without prolonging the duration of surgery. The other reason may be that NACT shrinks the tumor volume before surgery, which makes surgery easier.

The improvement in survival rates with NACT plus RST was not statistically significant. One explanation for this may be the variation in effectiveness of different neoadjuvant regimens. The trials included in our meta-analysis used cisplatin-based chemotherapy combined with irinotecan, paclitaxel, vincristine, mitomycin, vincristine, bleomycin, or 5-fluorouracil. To clarify the benefits of neoadjuvant chemotherapy, more potent regimens of chemotherapy, with various chemotherapy cycles, dose intensity, and diversity, should be explored. Additionally, the clinical response to NACT may depend on the pathological types of the cervical cancers, which include squamous cell carcinoma and adenocarcinoma. Some studies have indicated that poor outcomes are observed in adenocarcinoma. Recently, several new drugs have been developed and sensitivity has been improved. Moreover, the rate of postoperative adjuvant chemo-radiotherapy was lower in the NACT+RST group than in the RST group, which may have an effect on the long-term outcomes of NACT clinical responders.

Our study has several limitations. First, because of the retrospective nature of the study, clinical heterogeneity existed, such as different histological types and treatments, which may affect comparison of the clinical results. Second, data were pooled from studies with different inclusion criteria, and there was heterogeneity among the included studies. Future research should include subgroup analysis to further evaluate these two methods.

**Conclusion**

The findings of this study indicated that administration of NACT before radical surgery is an optimal treatment strategy for locally advanced cervical cancer, yielding an advantage in terms of reducing surgical risk without increasing difficulty of surgery or decreasing survival rate. Larger prospective trials with different neoadjuvant approaches are warranted to clarify the potential benefits of NACT.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This study was supported by Beijing Municipal Science and Technology Commission (grant nos. D151100001915001 and D131100005313009).

**ORCID iD**

Yu-Mei Wu  https://orcid.org/0000-0003-1186-7198

**References**

1. Koh WJ, Greer BE and Abu-Rustum NR. Cervical cancer. *J Natl Compr Canc Netw* 2013; 11: 320–343.
2. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. *J Epidemiol Biostat* 2001; 6: 7–43.

3. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. *Lancet* 1997; 350(9077): 535–540.

4. Lee DW, Lee KH, Lee JW, et al. Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer? *Int J Gynecol Cancer* 2013; 23: 1303–1310.

5. Disilvestro P, Ali S, Peter C, et al. A Gynecologic oncology group phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIB and IVA cervical carcinoma limited to the pelvis. *Gynecol Oncol* 2012; 125: S3–S4.

6. Zuliani AC, Barros Esteves SC, Teixeira LC, et al. Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIB epidermoid cervical cancer: a randomized controlled trial. *J Clin Oncol* 2014; 32: 542–547.

7. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. *J Clin Oncol* 2002; 20: 179–188.

8. Hwang YY, Moon H, Cho SH, et al. Ten-year survival of patients with locally advanced, stage Ib-IIb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. *Gynecol Oncol* 2001; 82: 88–93.

9. Zhao H, He Y, Yang S, et al. Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis. *Onco Targets Ther* 2019; 12: 1881–1891.

10. Toita T, Sakamoto K, Higashi M, et al. Therapeutic value of neoadjuvant intraarterial chemotherapy (cisplatin) and irradiation for locally advanced uterine cervical cancer. *Gynecol Oncol* 1997; 65: 421–424.

11. Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update for a nonrandomized comparison. *Int J Radiat Oncol Biol Phys* 1995; 31: 703–716.

12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). Cochrane Collaboration website. http://training.cochrane.org/handbook. Accessed November 22, 2017.

13. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Epidemiol. Biostat. Public Health* 2009; 6: e1–e34.

14. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: 889–893.

15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.

16. Yang Z, Chen D, Zhang J, et al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study. *Gynecol Oncol* 2016; 141: 231–239.

17. Behtash N, Nazari Z, Ayatollahi H, et al. Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB–IIA cervical cancer. *Eur J Surg Oncol* 2006; 32: 1226–1230.

18. Chen H, Liang C, Zhang L, et al. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: randomized study. *Gynecol Oncol* 2008; 110: 308–315.

19. Katsumata N, Yoshihara H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, II2A, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). *Br J Cancer* 2013; 109: 2505–2505.

20. Prueksaritanond N, Chaisarn P, Yanarapong M. The efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage IB2-IIA cervical cancer. *J Med Assoc Thai* 2012; 95(Suppl 3): S55.
21. Lee JY, Kim YH, Kim MJ, et al. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy. Arch Gynecol Obstet 2011; 284: 477–482.

22. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol 2007; 106: 362–369.

23. Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997; 67: 61–69.

24. Serur E, Mathews RP, Gates J, et al. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Gynecol Oncol 1997; 65: 348–356.

25. Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res 2006; 32: 315–323.

26. Wang Y, Wang G, Wei LH, et al. Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement. Chin J Cancer 2011; 30: 645–654.

27. Bogani G, Cromi A, Serati M, et al. A prospective case-control study on the impact of neoadjuvant chemotherapy on surgery-related outcomes of laparoscopic radical hysterectomy. Anticancer Res 2014; 34: 5703–5708.

28. Kim HS, Kim JH, Chung HH, et al. Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: primary surgical treatment versus neoadjuvant chemotherapy before surgery. Gynecol Oncol 2011; 121: 551–557.

29. Wen H, Wu X, Li Z, et al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer. Int J Gynecol Cancer 2012; 22: 296–302.

30. Cho YH, Kim DY, Kim JH, et al. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol 2009; 20:22–27.

31. Zhao H, He Y, Zhu LR, et al. Effect of neoadjuvant chemotherapy followed by radical surgery for FIGO stage IB2/IIB2 cervical cancer: a multi-center retrospective clinical study. Medicine (Baltimore) 2019; 98: e15604.

32. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

33. Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet 2006; 95: S43–S103.

34. Panici PB, Greggi S, Scambia G, et al. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 1991; 41: 212–216.

35. Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993; 49:156–165.

36. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010; 12: CD007406.

37. Kim HS, Kim JY, Park NH, et al. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIB cervical cancer. Gynecol Oncol 2010; 119: 217–224.

38. Hu T, Li S, Chen Y, et al. Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria. Eur J Cancer 2012; 48: 2353–2360.

39. Fujiwaki R, Iida K, Ohnishi Y, et al. Intraarterial neoadjuvant chemotherapy followed by radical surgery and radiotherapy for stage IIb cervical carcinoma. Anticancer Res 1997; 17: 3751–3755.

40. Vizza E, Pellegrino A, Milani R, et al. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIIB cervical cancer patients after
neoadjuvant chemotherapy. *Eur J Surg Oncol*, 2011, 37: 364–369.

41. Rose PG, Java JJ, Whitney CW, et al. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. *Gynecol Oncol* 2014; 135: 208–212.

42. He L, Wu L, Su G, et al. The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer. *Gynecol Oncol* 2014; 134: 419–425.

43. Chen LY, Huang CY, Huang YS, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. *Acta Obstet Gynecol Scand* 2014; 93: 661–668.